Dr Reddy's Laboratories today launched Somazina, a drug used to treat patients who have suffered from stroke, in India.
The Hyderabad-based firm has partnered with Spain's Ferrer Internacional SA to make Somazina available in India, Dr Reddy's Laboratories Ltd said in a statement.
Somazina is used for the management of stroke and has been used for the treatment of post-stroke patients around the world.
It is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries.
"We are excited about the partnership with Ferrer and launch of Somazina which addresses significant unmet need in patients, whose quality of life gets severely compromised after having a stroke," said Alok Sonig, Senior Vice President and Head of India Business, Dr Reddy's Laboratories.
With the launch of Somazina and recent acquisition of Nootropil through the UCB brands' acquisition, the company looks forward to building its presence in the neurology segment, he added.
Dr Reddy's Laboratories shares closed 0.52 per cent down at Rs 3,491.60 apiece on the BSE.